Accounting for trial effects (TEs) on survival in patients with a normal karyotype given gemtuzumab ozogamicin (GO) with or without interleukin 11 (IL-11) or idarubicin plus cytosine arabinoside (IA)
| Confounded GO/TE, posterior mean (SD) . | Assumed TE, posterior mean (SD) . | GO effect, posterior mean (SD) . | Posterior probability that GO with or without IL-11 was inferior to IA . |
|---|---|---|---|
| 0.823 (0.323) | 0.396 (0.318) | 0.427 (0.444) | 0.832 |
| 0.823 (0.323) | −0.396 (0.318) | 1.219 (0.444) | 0.997 |
| 0.823 (0.323) | 0.328 (0.291) | 0.495 (0.444) | 0.868 |
| 0.823 (0.323) | −0.328 (0.291) | 1.151 (0.444) | 0.995 |
| Confounded GO/TE, posterior mean (SD) . | Assumed TE, posterior mean (SD) . | GO effect, posterior mean (SD) . | Posterior probability that GO with or without IL-11 was inferior to IA . |
|---|---|---|---|
| 0.823 (0.323) | 0.396 (0.318) | 0.427 (0.444) | 0.832 |
| 0.823 (0.323) | −0.396 (0.318) | 1.219 (0.444) | 0.997 |
| 0.823 (0.323) | 0.328 (0.291) | 0.495 (0.444) | 0.868 |
| 0.823 (0.323) | −0.328 (0.291) | 1.151 (0.444) | 0.995 |